Essais liés8clinical trials
VilleBrnolocalisation
PaysCzechialocalisation
SourcelocaleCSV/MySQL

Informations

centre

Synchronisé depuis ClinicalTrials.gov — NCT06293365

Ouvrir le site du centre

Essais cliniques associés

8
MoléculeIndication / populationPhaseNCTTitreStatut
Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL Maladie coronarienne Phase 3 NCT05739383 A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients. ACTIVE_NOT_RECRUITING
VHB937 Alzheimer Phase 2 NCT07094516 A Clinical Trial to Learn About the Effects of VHB937 in People With Early Alzheimer's Disease ACTIVE_NOT_RECRUITING
Pelacarsen (TQJ230) Accident vasculaire cérébral Phase 3 NCT07517263 An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230) ACTIVE_NOT_RECRUITING
VAY736 1ml PFS Lupus Phase 2 NCT06293365 Two-period Crossover Study to Demonstrate the Comparability of Pharmacokinetics of Subcutaneous Ianalumab Between 2mL Auto-injector/2mL PFS with1mL Pre-filled Syringe in Adult Participants With Autoimmune Disease ACTIVE_NOT_RECRUITING
Remibrutinib (Blinded) SEP Phase 3 NCT07225504 REMASTER — A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis RECRUITING
Ianalumab Lupus Phase 3 NCT05639114 Phase 3 Study to Evaluate Two Regimens of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 1) ACTIVE_NOT_RECRUITING
Remibrutinib oral treatment SEP Phase 3 NCT06846281 Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis. RECRUITING
Ianalumab Lupus Phase 3 NCT06133972 SIRIUS-SLE LTE — Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension). RECRUITING